2024 Sales Forecast: Unprecedented Growth on the Horizon

   bonyf NV / Key word(s): Results Forecast/Annual Results
   2024 Sales Forecast: Unprecedented Growth on the Horizon
   10-May-2024 / 15:05 CET/CEST
     ____________________________________________________________

   
   2024 Sales Forecast: Unprecedented Growth on the Horizon

   Image link:
   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=9e9d6736ba6329403e0198398ad9ed60
   Image title: Image1-0

   Ghent (Belgium), 10 May 2024, 6:00 a.m.; bonyf NV (Mnemonic:
   MLBON), the next-generation oral comfort expert, is a Euronext
   Paris listed company and specializes in the development,
   production and marketing of oral, denture, orthodontic and wound
   care products, is poised for exponential growth in 2024.

Introduction

   The bonyf achievement of compliance with the stringent European
   Medical Device Regulation (MDR) has significantly bolstered our
   market position and enhanced our credibility as a reliable and
   sustainable manufacturer.

   Leveraging our compliance status and unique product offerings,
   nurture our new business model implemented since end 2022 whereas
   bonyf establishes itself a significant global player in contract
   manufacturing. Our contract manufacturing (or private label)
   sales YTD increased from 37% in 2023 towards 70% in 2024. Leading
   country supermarkets and international drugstores perform on long
   duration contracts as to ensure the sustainable sales growth
   since 2023.

   Image link:
   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=7602be3fafd3e2b7d2464b722f5af559
   Image title: Image22

Market

   The global demand for oral hygiene products continues to soar,
   driven by increasing awareness of oral health and hygiene among
   consumers worldwide. bonyf belongs to the limited number of
   independent manufacturers for dental effervescent tablets in
   Europe and MDR certification successfully completed, we enjoy a
   competitive advantage in terms of market share and positioning.

   bonyf uniqueness exist by not only providing the standard omni
   present formulations but by proposing its own developed healthy,
   more efficient and performant and patented formulations developed
   by bonyf own R&D department. "Our goal is to develop a product
   that not only provides exceptional performance but also promotes
   overall oral health".

   The unique denture cleansing tablets performance by the
   formulation named NitrAdine showing the best-in-class
   disinfection efficiency LOG 5, or disinfecting the denture with
   99,999%.

   The unique healthy denture fixative cream including its patented
   formulation replacing mineral oils by olive oil showing the
   growing recognition of our "Olivafix Gold" brand in the denture
   fixative creams segment.

   bonyf R&D pushing further on the healthiness and uniqueness
   mission by realizing the new Olivafix Alginate-organic
   formulation as to become not only best in performance strong hold
   with 24h* strong hold of the upper dentures, but most healthy
   denture fixative cream ever formulated. bonyf R&D ensuring future
   unique products. The growing recognition of our "Olivafix Gold"
   brand in the denture fixative creams segment further enhances our
   market presence and customer appeal, with rising inquiries and
   demand for our patented product.

Sales Forecast

   With current negotiations pushing on the contract manufacturing
   sales part, bonyf is heading to a unprecedent, well balanced and
   sustainable sales result in 2024.

Conclusion

   In summary, the year 2024 promises to be a landmark period for
   our company, characterized by unparalleled growth and expansion
   in both sales volume and revenue. Our compliance with the
   European MDR, coupled with our innovative product offerings and
   growing market recognition, positions us for sustained success in
   the years ahead.

   With firm orders already in place and increasing demand for our
   products, we are confident that 2024 will mark a pivotal
   milestone in our journey towards becoming a dominant force in the
   global oral hygiene products market.

   bonyf's strengths
     * Products with patented formulations
     * Produced in Switzerland compliant with stringent
       international quality regulations
     * Proven clinical efficacy
     * Commercial presence in 37 countries
     * Prospects for solid growth and rapid profitability
     * A fast-growing oral and dental care market

   Image link:
   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=3df48fc4b6cac91225c8cf3c4edd9408
   Image title: Image33

About bonyf

   Incorporated in 1979, bonyf specialises in the development,
   production and selling of cutting-edge oral & dental care
   products. bonyf is a forward-thinking company committed to
   revolutionizing oral care through innovation and research. With a
   focus on quality and efficacy, bonyf develops cutting-edge
   products designed to enhance the well-being of individuals
   worldwide. Through its unwavering commitment to innovation and
   continuous improvement, bonyf makes a real difference to people
   suffering from dental and oral conditions. The company has its
   R&D facilities in Liechtenstein (in the renown dental valley), a
   production plant in Switzerland and distributes its product range
   in 37 countries worldwide. Benefiting from seven patent protected
   formulations and products developed in-house, bonyf expects
   strong future development, driven by the fast-growing oral and
   dental care market.

   For more information about bonyf and its innovative oral care
   products, please visit www.bonyf.com.

bonyf

Jean-Pierre Bogaert

investor@bonyf.com

   Image link:
   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=7ddef1551a397af2f57b827400b07df1
   Image title: Image44

____________________________________________________________

   Dissemination of a Financial Wire News, transmitted by EQS Group.
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   Language:    English
   Issuer:      bonyf NV
                Doornzelestraat 114 D
                9000 Gent
                Belgium
   Phone:       +41 79 412 42 79
   E-mail:      president@bonyf.com
   Internet:    www.bonyf.com
   ISIN:        BE6333353298
   EQS News ID: 1900677

   End of Announcement - EQS News Service
     ____________________________________________________________

1900677 10-May-2024 CET/CEST